A
Alison L. Hannah
Researcher at Pfizer
Publications - 89
Citations - 4044
Alison L. Hannah is an academic researcher from Pfizer. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 24, co-authored 84 publications receiving 3052 citations. Previous affiliations of Alison L. Hannah include Max Planck Society.
Papers
More filters
Journal ArticleDOI
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K. Litton,Hope S. Rugo,Johannes Ettl,Sara A. Hurvitz,Anthony Gonçalves,Kyung Hun Lee,Louis Fehrenbacher,Rinat Yerushalmi,Lida A. Mina,Miguel Martin,Henri Roché,Young-Hyuck Im,Ruben G.W. Quek,Denka Markova,Iulia Cristina Tudor,Alison L. Hannah,Wolfgang Eiermann,Joanne L. Blum +17 more
TL;DR: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single‐agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression‐free survival.
Journal Article
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
D B Mendel,A D Laird,B D Smolich,R A Blake,Congxin Liang,Alison L. Hannah,R M Shaheen,L M Ellis,Steven D. Weitman,Laura K. Shawver,Julie M. Cherrington +10 more
TL;DR: This work focuses on SU5416, a selective inhibitor of VEGF receptors that is currently in clinical development for the treatment of advanced malignancies and its biochemical, biological and pharmacological properties are reviewed and clinical implications discussed.
Journal Article
Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies,
Cheryl A. London,Alison L. Hannah,Regina Zadovoskaya,May B. Chien,Cynthia Kollias-Baker,Mona P. Rosenberg,Sue Downing,G. S. Post,Joseph F. Boucher,Narmada Shenoy,Dirk B. Mendel,Gerald McMahon,Julie M. Cherrington +12 more
TL;DR: This study provides the first evidence that p.o. administered kinase inhibitors can exhibit activity against a variety of spontaneous malignancies in dogs, and it is likely that such agents will demonstrate comparable antineoplastic activity in people.
Journal ArticleDOI
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
Paul G. Richardson,Marcie L. Riches,Nancy A. Kernan,Joel A. Brochstein,Shin Mineishi,Amanda M. Termuhlen,Sally Arai,Stephan A. Grupp,Eva C. Guinan,Paul L. Martin,Gideon Steinbach,Amrita Krishnan,Eneida R. Nemecek,Sergio Giralt,Tulio E. Rodriguez,Reggie E. Duerst,John Doyle,Joseph H. Antin,Angela R. Smith,Leslie Lehmann,Richard E. Champlin,Alfred P. Gillio,Rajinder P.S. Bajwa,Ralph B. D'Agostino,Joseph M. Massaro,Diane Warren,Maja Miloslavsky,Robin Hume,Massimo Iacobelli,Bijan Nejadnik,Alison L. Hannah,Robert J. Soiffer +31 more
TL;DR: Defibrotide was associated with significant improvement in day +100 survival and CR rate and the historical-control methodology offers a novel, meaningful approach for phase 3 evaluation of orphan diseases associated with high mortality.
Journal ArticleDOI
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Francis J. Giles,Alison Stopeck,Lewis R. Silverman,Jeffrey E. Lancet,Maureen Cooper,Alison L. Hannah,Julie M. Cherrington,Anne Marie O'Farrell,Helene A. Yuen,Sharianne G. Louie,Weiru Hong,Jorge E. Cortes,Srdan Verstovsek,Maher Albitar,Susan O'Brien,Hagop M. Kantarjian,Judith E. Karp +16 more
TL;DR: Single agent SU5416 had biologic and modest clinical activity in refractory AML/MDS and studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML or MDS.